[A20-71] Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V
Last updated 16.11.2020
Project no.:
A20-71
Commission:
Commission awarded on 12.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Indication:
| Adults with chronic progressive fibrosing interstitial lung diseases other than SSc-ILD or IPF |
Result of dossier assessment:
| The advantage in the outcome category of morbidity is accompanied by disadvantages in side effects; indication of minor added benefit |
| Project no. | Title | Status |
|---|---|---|
| A19-36 | Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G15-03 | Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A15-01 | Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A20-124 | Nintedanib (interstitial lung disease) - Addendum to Commission A20-71 | Commission completed |
| A20-70 | Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-30 | Nintedanib (fibrosing interstitial lung diseases, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-29 | Nintedanib (systemic sclerosis associated interstitial lung disease, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-02-04: A G-BA decision was published.